B-Cell Malignancies Articles A specially curated list of peer-reviewed articles discussing the latest advancements in treatment of B-cell malignancies. Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials READ MORE BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib READ MORE Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis READ MORE MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study READ MORE BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies READ MORE Management of relapsed/refractory Chronic Lymphocytic Leukemia READ MORE Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma READ MORE Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG) READ MORE Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis READ MORE Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib READ MORE Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib READ MORE The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma READ MORE Management of cardiovascular complications of bruton tyrosine kinase inhibitors READ MORE Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial READ MORE Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors READ MORE Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy READ MORE Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies READ MORE Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances READ MORE How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia READ MORE Facebook Twitter Linkedin
